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Regenerative therapies possess high theoretical potential for medical advance yet their success as commercial
therapeutics is still open to debate. Appropriate data on target opportunities that provide perspective and enable
strategic decision making is necessary for both efficient and effective translation. Up until now, this data have
been out of reach to research scientists and many start-up companies—the very groups currently looked to for
the critical advance of these therapies. The target-based estimate of opportunity presented in this report dem-
onstrates its importance in evaluating medical need and technology feasibility. In addition, analysis of U.S.
research spending, productivity, and innovation reveals that U.S. basic research in this field would benefit from
greater interdisciplinarity. Overcoming the barriers that currently prevent translation into high value therapies
that are quickly clinically adopted requires simultaneous integration of engineering, science, business, and
clinical practice. Achieving this integration is nontrivial.
Introduction
In 2009, demonstrating the value of medical innovationwas identified as the primary risk factor in life science
development going forward.1 There is an increasing chal-
lenge in biotechnology and pharmaceutical research to not
only push into new technologies but also translate those ef-
forts into true medical breakthroughs.
The pressing need for innovative therapies in pharma-
ceutical pipelines,2 the move to more personalized medicine
as an area for future pharmaceutical company growth,3 and
the growing interest in orphan indications4 suggest that the
time is right for regenerative therapies. The tissue engineer-
ing or broader regenerative medicine, and regenerative
medicine, and stem cell research (RMSCR) fields have been
long viewed by governments5,6 and researchers as areas
where the potential for medical breakthroughs is high.
Interestingly, commercial translation remains significantly
less than many other areas of biotechnology and medical
devices. Over the last 25 years, large medical device and
pharmaceutical companies have struggled to generate a re-
turn on investment in regenerative therapies. While many
companies wait on the sidelines for a clearer indication that
regenerative therapies are medically and commercially fea-
sible, it would behoove those engaged in the field to deter-
mine the underlying reasons for the differences between
expectations and deliverables. Manufacturing and regulatory
pathways for regenerative therapies are less clear than for
traditional pharmaceuticals and the fit between large com-
pany core competencies and the needs of regenerative ther-
apy development is weak. As a new technology area,
RMSCR still represents uncharted territory for most phar-
maceutical and medical device companies. This implies that
not only must the scientific basis be sound, but also the
supporting technology, medical use, and commercial strat-
egy must be developed enough to seem plausible in a field
where some issues will be addressed for the first time. Any
disruptive technology faces the same challenges that RMSCR
faces, and addressing them head on is, we believe, the most
effective way to drive progress forward. Fortunately interest
in RMSCR has existed for quite some time, and a wealth of
science and technology to build upon has been generated.
The U.S. clinical use of laboratory-grown cells as trans-
plants dates back to the 1980s.7 The first living engineered
tissue gained U.S. Food and Drug Administration (FDA)
approval in 1998.8 Also, beginning in 1998, the possibilities
for regenerative therapies progressively expanded with the
ability to grow human embryonic stem cells,9 the realization
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that adult stem cells retained multipotency,10 and now, the
technical developments of being able to induce pluripotency
in mature adult cells by a variety of methods.11–13
From a translational perspective, the most valuable data is
actionable—capable of driving a science forward, not simply
expanding it outward. Over the last decade, we have pri-
marily seen the expansion of possibilities in RMSCR, par-
ticularly in the stem cell area. However, the reality of
translation is that not every possibility will be equally fea-
sible or reasonable. Eventually, a line of effort must focus on
meeting a specific medical objective that also fulfills com-
mercial requirements. Not all objectives will be of equal
medical importance or value. We hypothesize that a clearer
understanding of the merits of those objectives early on will
increase the efficiency and effectiveness of translation from
the start.
As we discuss herein, highly pertinent data on target op-
portunities, where indications can be studied in perspective,
can be a valuable tool in translational RMSCR research. This
type of information is generally unavailable to most research
scientists and small start-up companies. A recent survey of
those involved in tissue engineering in academic and in-
dustry listed ‘‘orienting research to market needs’’ as the
second most difficult self-ranked hurdle for academics, and
‘‘maintaining focus in an evolving market’’ as the most dif-
ficult for development-stage companies.14 A 2008 report by
the U.K.’s Bioscience Innovation & Growth Team (BIGT)6
noted that ‘‘industry cannot deliver continued healthcare
improvements by itself’’ and that a cultural shift in university
biomedical research where translation of research and busi-
ness engagement becomes a core mission is important both
to the future of bioscience and economic development. In our
view, it is not a matter of limiting scientific freedom or
abandoning basic research for mundane practicality or
purely commercial considerations, but rather acknowledging
the most suitable endpoints and challenging even those in
basic research to be cognizant of the medical targets in a way
that helps them to look ahead to the pivotal issues that will
either enable or prevent translation. As we learn more it will
be vital to also point out where basic research can play a key
role, and to couple that to further developments.
This report is not meant to be encyclopedic nor an ex-
haustive list of all possible applications of tissue engineering
or stem cells. Rather, this first report in our series of studies is
meant to supply important objective data in perspective re-
garding the medical need for regenerative therapies in the
strictest sense, that is, for the most part homologous thera-
pies that are formed or work through a regenerative mode of
action to repair, restore, enhance, or replace lost tissue
function. This report is intended to act as a stimulant for
discussion of these issues and the sharing of critical data.
The underlying premise of the first objective of this study
is that effective translation of science and medicine requires
the identification of appropriate targets in a way that enables
strategic decisions. Therefore our first goal was to study
disease and procedure incidence of regenerative therapy
targets in a way that (1) provided a true estimate of the
medical need for a regenerative therapy within a diagnosis
or procedure group, (2) could be used to determine the target
population within that group, (3) could be used to better
match a treatment approach to the medical need, and (4)
could illuminate the opportunities for leveraging scientific
knowledge, expertise, and technology (likely to be a key
factor in achieving a sufficient return on investment for many
RMSCR applications).
The impetus for research and innovation in RMSCR cur-
rently falls on government funding and academic science in
the United States. Therefore, the second goal of our study
was to assess the current status of U.S. RMSCR research and
innovation using newly available government data. This
data can objectively measure the present level of scientific
productivity and innovation in relevant government-funded
RMSCR research. Of interest was determining how U.S. basic
research matched the principal medical needs identified in
the estimate of opportunity analysis (EOA). By making data
from a detailed EOA specific to regenerative therapies
broadly accessible and establishing a baseline of current re-
generative medicine output and innovation, we would now
be in a position to test our hypothesis that a clearer per-
spective of the relative target opportunities can improve the
connectivity between scientific, medical, and commercial
objectives. Establishing this connectivity will be vital to the
future of regenerative medicine since the ultimate value to
society lies in what benefits the resulting therapy will mean
for the patient. The ability to get the therapy to the patient
who needs it requires commercial feasibility, or at the very
least financial feasibility.
Going forward our plan is to develop metrics that can
objectively measure changes in this connectivity and its im-
pact on productivity and commercial translation over time.
To further test the benefits of this knowledge and foster the
evolution of how regenerative medicine is tackled, we will
continue to develop more in-depth opportunity analyses in
key medical areas identified by the EOA. In the second phase
of our work we are studying the gap between regenerative
technology and specific medical needs as well as the state of
the science across the multiple disciplines likely to be needed
to close these gaps. Our hypothesis is that this growing body
of knowledge and information will make it ever easier to
recognize not only the best medical and commercial oppor-
tunities for regenerative therapies but also the best and most
efficient way forward.
Methods
Estimate of target opportunities
Limits to the incidence data. The estimate of target op-
portunities, while comprehensive, does not attempt to
quantify the entire market for RMSCR and everything cells
and/or biomaterials could be used for. Rather, we focused
on the opportunities where cells and/or biomaterials might
be used to enhance, augment, restore, regrow, and re-
establish normal tissue, which we refer to as ‘‘regenerative
therapies’’ in recognition of their principal biological action.
For this reason, the use of cells simply as drugs or in non-
homologous applications, such as their use for the purpose of
immune suppression, was considered beyond the scope of
the current study even though we recognize it as an active
area of research with several potential medical uses.
In addition, because we have relied on data from the
National Hospital Discharge Survey (NHDS), incidence
analysis is limited to disorders requiring hospitalization.
Therefore disorders treated on an outpatient basis will not be
captured in the NHDS data, such as many wound healing
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procedures not requiring skin grafting and most ophthalmic
procedures.
To collect relevant NHDS data for regenerative therapies
required, forming a detailed list of regenerative targets based
on International Classification of Diseases, 9th Revision,
Clinical Modification (ICD-9-CM) codes down to billable
code. We recognize that ICD-9-CM codes are by nature not
patient specific, but they represent an excellent starting point
for differentiating between clinically adoptable opportuni-
ties. Most therapies that could in some way enable or achieve
tissue repair and regeneration were included without dis-
tinction of type of technology that is, or could be, used to
achieve the therapeutic goal. However, the scope of the op-
portunity analysis was limited to targets that could be helped
through a regenerative mechanism. Due to the size of the
study, analysis of the intersection of regenerative medicine
and cancer was not included. In addition, discussion of
the medical application of stem cell therapies often includes
the treatment of inflammatory and autoimmune disorders,
but their different biologic, mechanistic, and therapeutic
considerations also necessitated placing these disorders
outside the scope of the current study. Nevertheless, our
more stringent parameters included activities currently cat-
egorized as regenerative medicine, tissue engineering, and
stem cell therapy—encompassing opportunities for factors,
biological matrices, cells, and combination products.
Discharges are reported in the NHDS by first-listed diag-
nosis, which is also the principal diagnosis and primary
reason for hospitalization. Up to seven diagnoses and up to
four procedures are listed for each discharge. Because many
of the treatment targets are as yet unmet, incidence based on
principal diagnoses alone may list as treatment of sequelae
rather than the treatment target, which may only appear as a
secondary diagnosis. To allow for this possibility, data for
the incidence of culled ICD-9-CM codes captured both first-
and second-listed (secondary) diagnoses. Data for all listed
diagnoses were collected for comparison.
Medical information about patients includes diagnoses
and procedures coded using the ICD-9-CM codes. ICD-9-CM
codes were reviewed down to billable code in both diagnosis
and procedure categories and culled of codes of minimal
relevance to use of a regenerative therapy. Estimates of in-
cidence for the remaining ICD-9-CM codes were made using
the Center for Disease Control’s National Center for Health
Statistics database. Estimates of incidence were captured for
first and second diagnoses and all diagnoses. The NHDS is a
national probability survey designed to meet the need for
information on characteristics of inpatients discharged from
nonfederal short-stay hospitals in the United States. From
1988–2007 the NHDS collected data from a sample of
*270,000 inpatient records acquired from a national sample
of about 500 hospitals through 2006. Only hospitals with an
average length of stay of fewer than 30 days for all patients,
general hospitals, or children’s general hospitals are included
in the survey.
The design of the NHDS requires that the survey data be
inflated or weighted to produce national estimates.15 There
are three components to the final weight: inflation by recip-
rocals of the probabilities of sample selection, adjustment for
nonresponse, and population weighting ratio adjustments. A
detailed explanation of how NHDS data is gathered and
calculated can be found in Dennison et al.16 The size of the
treatment opportunity was calculated for years 2004–2006
using the SAS Ver. 9.2 (Cary) statistical programming
package. The findings and conclusions derived from this
data are those of the authors and do not necessarily represent
the views of the Research Data Center, the National Center
for Health Statistics, or the Centers for Disease Control and
Prevention.
Evaluation of basic research productivity
and innovation
Data sets on National Institutes of Health (NIH) research
spending were obtained using a beta version of the NIH
Research Portfolio Online Reporting Tools (RePORT) and an
additional RePORT data summary on NIH Estimate of
Funding.17 Data sets were downloaded and analyzed using
Microsoft Excel. The correlation of different parameters
within the NIH data sets was estimated using the correlation
coefficient function in Microsoft Excel. In addition to detailed
project information, data on patents citing support from the
listed projects and publications citing support from the listed
projects were collected from the RePORT query. It was noted
that, in the RePORT data, publications citing support from
more than one project counted as a publication for each
project so the number of total publications did not represent
an absolute number of articles but rather a measure of
scholarly output from the research. Since publications are the
primary measure of scholarly output, we believed that this
measure was necessary and despite its limitations, identified
overall productivity and trends even though counting some
publications more than once.
While the use of patents as a direct measure of innova-
tion can be debated, patents represent inventions that
are sufficiently novel or innovative over state-of-the-art.
Patent protection is important to commercialization. Patents
are a necessary component protecting a company’s tech-
nology as well as freedom to practice. It is therefore an
important component in funding of commercial develop-
ment, from venture capital and from government programs
like the Small Business Innovation and Research Grants as
well as interest by larger companies and potential partners.
Therefore some measure of patents was important in the
evaluation of U.S. productivity and innovation since our
focus was on commercial translation. The RePORT patent
data for the data sets appeared to contain prior patents re-
lated to the listed research or investigator, not exclusively
inventions funded during the 2008–2009 period and as
such more accurately represented the intellectual property
foundation being built upon rather than a specific number
of inventions stemming from 2008–2009 funding. The
RMSCR data set was created by querying the NIH spend-
ing categories Regenerative Medicine and Stem Cell Re-
search for years 2008 and 2009 across all NIH institutions.
Since each research grant can fall into multiple categories,
Regenerative Medicine and Stem Cell Research categories
overlapped but neither was all inclusive. Tissue engineering
is not listed as a category, likely usurped by the broader
Regenerative Medicine category. Because we wished to col-
lect data specific to tissue engineering, we also queried the
database using either the key term ‘‘tissue engineering’’ or,
for comparison, ‘‘stem cells’’ in years 2008–2009 across all
spending categories.
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The subset of most active RMSCR institutions was obtained
by selecting for institutions within the RMSCR group with 10
or more distinct projects during 2008–2009 and ‡ $10 million
dollars in total funding for the 2 years. Cancer research in-
stitutions were not included. Universities with more than one
site were combined with the exception of the University of
California, because of their size, were kept as individual in-
stitutions except as noted below. Institutes with a primary
focus on cancer research were excluded from the most active
list. For comparison, funding data from the ‘‘tissue engineer-
ing’’ and ‘‘stem cells’’ data sets were pulled for each institution
identified as most active within the RMSCR group.
Pending U.S. patent applications for the field, as well as
each of the most active RMSCR institutions was obtained
using a U.S. Patent and Trademark Office online patent
search and key terms. Pending patent data could not be
distinguished for individual sites within a university system
and so RePORTer data for the University of California in-
stitutions were combined where projected patents were an-
alyzed. RMSCR patent application data from 2001 to
September 2010 were obtained from the U.S. Patent and
Trademark Office Web site (http://patft.uspto.gov) by per-
forming a search of all patent applications containing in their
title or abstract—one or more of the following Boolean search
terms: ‘‘regeneration,’’ ‘‘stem cell(s),’’ ‘‘tissue engineered,’’
‘‘tissue repair,’’ ‘‘tissue regeneration,’’ ‘‘progenitor,’’ ‘‘organ
repair,’’ ‘‘biological scaffold,’’ or ‘‘tissue scaffold’’ with and
without an institution as the assignee.
Results
Results of the estimate of opportunity analysis
Analysis of the data was performed using a top-down
approach to establish and maintain perspective on the relative
nature of the target opportunities. Our goal was to objectively
determine the relative extent of the opportunities for regen-
erative therapies in hospitalized patients letting the numbers
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FIG. 1. Overview of the estimate of opportunity for regen-
erative therapies. The data estimate the relative opportunity
for regenerative therapies in U.S. hospitalized patients across
major medical areas for years 2004–2006. Data source: Na-
tional Hospital Discharge Survey, Centers for Disease Control
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FIG. 2. The incidence of hospital procedures across major
medical areas. The graph and table show the relative inci-
dence of U.S. hospital procedures applicable to regenerative
therapies across major medical areas for years 2004–2006. (A)
Relative incidence of the most prevalent repair procedures.
(B) Relative incidence of the less prevalent repair procedures.
142 PARENTEAU ET AL.
diagnoses and procedures (Fig. 1), there are over 8 million
discharged patients per year in the United States who are
candidates for a regenerative therapy as defined in this study.
Cardiovascular and peripheral vascular targets were
combined as a Cardio/Vascular group because many re-
generative therapies could be leveraged to meet targets in
both. Total incidence within the broad disease categories was
sorted into four tiers (Fig. 1A). Incidence ranked Cardio/
Vascular as the primary area of opportunity (43%–45%) fol-
lowed by musculoskeletal diseases (29%), central and pe-
ripheral nerve diseases (11%–12%), and genetic and
metabolic disorders (9%), represented a second tier. Integu-
ment and congenital disorders represented 2%–4%. Opthal-
mic targets of opportunity that do not currently result in
hospitalization would not be captured in this analysis.
Clearly, vision restoration is likely to be a significant target
for development but its study requires data beyond the
scope of this analysis. This is also true for other indications
that maybe largely treated in an outpatient setting.
Procedures that could be improved or better enabled by a
therapy that stimulates regeneration, or the restoration of
functional tissue in the major areas of cardio- and peripheral
vascular disease, skeletal, and brain and nerve-related repair
numbered over 5 million over the 3-year period between
2004 and 2006 (Fig. 2A) with approximately another 500,000
other assorted soft tissue repair procedures per year (Fig. 2B).
The NHDS incidence of liver and pancreas transplantation
for genetic and metabolic diseases varied widely year to
year, markedly increasing in 2006 to 4,598 liver transplant
procedures and 3,660 pancreas transplant procedures (data
not shown), perhaps due to new surgical innovations. Pan-
creatic islet transplants were estimated at 759 in 2006.
The top-down approach identified the areas with the larg-
est concentration of target opportunities and prompted us to
begin to examine the opportunities making up the top two
tiers in more detail. Several considerations that could impact
the clinical adoption of a regenerative therapy came to light.
Cardiovascular and peripheral vascular disease
As might be expected, problems of the heart and vascu-
lature represented the largest target areas for regenerative
therapies (Fig. 3A). Cardiovascular targets make up 96% of
the opportunity although the incidence of peripheral vascu-
lar targets is still significant. Heart failure is the most pro-
minent target within ischemic heart disease (Fig. 3B).
Treatment or prevention of heart failure represents major
treatment opportunities for stem cell therapy if the therapy
would be able to stop progression of cardiac degeneration
after acute myocardial infarction (AMI) or would be able to
regenerate functional heart muscle in degenerated, scarred,
and weakened myocardium, respectively—both different
biological targets with different levels of scientific and
medical challenge.18–20
For effective translation, consideration of the medical need
is as important as overcoming a technological challenge. The
EOA data revealed that the current management of acute
cardiovascular disease appears to work well. Ninety-seven
percent of all cardiac disease patients from 2004 to 2006 were
discharged alive, but of those, 11% were discharged to long-
term care facilities and 65% of the long-term care patients
had a primary or second-listed diagnosis of heart failure
representing over 1.1M discharges over the 3-year period.
Patients within the long-term care group would likely be in
most need of a regenerative therapy capable of restoring
functional cardiac muscle. The benefit of early intervention
would be reduction of the rate and/or incidence of pro-
gression to heart failure. Given what appears to be the suc-
cessful management of acute cardiac disease, administration
of cardiac repair cells at the time of AMI should limit the
progression to heart failure to be of ultimate value to the
patient and medical system, not simply improve the left
ventricular ejection fraction short term. As the EOA data
clearly indicate, the greatest medical benefit for a regenera-
tive therapy will not be in the short term for most cardiac
disease patients.21 This may pose a challenge for products
approved based on near-term endpoints like improvement of
ventricular function without a connection to long-term out-
comes and may effect reimbursement and the rate of market
acceptance until clinical data demonstrating the therapy’s
ultimate value is either empirically gathered over time, or
helped by preclinical models that can establish the connec-
tivity between near- and long-term outcomes. These chal-
lenges will not be unique to the cardiovascular space.
Further stratification of the peripheral vascular opportunity
into potential drug or cell therapy targets versus potential
vascular graft targets was done by combining the incidence of
generalized symptoms, pain, and intermittent claudication, or
ulceration, gangrene, and bypass grafting, respectively (Fig.
3C). Peripheral vascular disease represents a significant target
opportunity for tissue engineering if it is able to deliver a sur-
gically acceptable, small-caliber vascular graft of sufficient
length that retains long-term patency.While cell-based therapy
to stimulate revascularization and small-caliber grafts may
reach a different primary demographic within the target pop-
ulation, they may also be synergistic if the efficacy of the
combined treatments justifies the costs. An important return on
investment consideration for vascular graft technology is that
vascular tissue engineering processes and expertise might also
be leveraged to address mid- to large-caliber graft opportuni-
ties in vascular access, for example. Indeed, vascular access
may be the first medical indication for these grafts and could
serve as an important step in gaining regulatory and clinical
acceptance of the technology. However as products, biologic
therapies targeting vascular access will have to deliver sub-
stantially better performance and/or outcome than currently
used devices and processed tissues to justify a higher cost in
most cases. The EOA data estimate that there are 600,000 or
more hemodialysis discharges a year. Drilling further into the
EOAdata reveals that AV grafts number*33,000 per year and
that there are 12,000 to 18,000 discharges for revision of arte-
riovenous grafts per year, which seems an obvious first-target
population. However, the greatest medical value may be in
providing an easier and faster alternative to the medically
preferred arteriovenous fistula and reducing the large number
of complication-plagued venous catheters used.22 The oppor-
tunities for the application of tissue engineering and stem cells
in revascularization, bypass, and vascular access will be cov-
ered in greater detail in Part II of this series of reports that
compares detailed incidence data with a gap analysis of med-
ical needs.
The most prominent endocardial repair procedure is the
replacement of heart valves. An estimated 80,000 valve re-
placements are performed per year, 70,000 of those are tissue
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valves. Implanted porcine valves can last up to 30 years,23
creating a significant barrier to entry for any new tissue
technology. Where current tissue valves meet less of the
medical need is in the pediatric patient where the perfor-
mance of mechanical valves is poor and tissue autografts
(which can grow) or human allografts are used.24 The ideal
valve alternative would mitigate the need for extended use
of anticoagulants and the need for progressive valve re-
placements as the child grows. EOA data estimate the total
incidence of congenital valve defects for 2004–2006 at be-
tween *16,000 and just over 22,000 based on primary and
second-listed diagnoses, significantly less than the adult in-
cidence. Heart valve replacement in a young child is a high-
risk procedure.23 In a study of 146 patients under 18 years of
age, freedom from reoperation was 54%– 8.1% for homo-
graft and 68%– 11.1% for autograft (the Ross procedure us-
ing pulmonary valve autograft) at 15 years.24
One difficulty in proving the superior benefit of human
valves compared to prosthetics is that in this patient popu-
lation, experience with prosthetic valves has shown that the
patient is a larger determinant of long-term outcome than the
device.24 This could be an even greater hurdle for an en-
gineered tissue graft compared against an allograft where
differences comparing tissue against tissue may be subtler.
This suggests that even a technically perfect tissue en-
gineered valve would meet with several challenges beyond
the science and engineering. It may help to explain why
the outstanding science and engineering performed to date
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FIG. 3. An estimate of cardiovascular and peripheral vascular treatment opportunities in U.S. hospitalized patients for years
2004–2006. (A) Relative incidence of cardiovascular and peripheral vascular disorders. (B) Breakdown of cardiovascular
incidence. (C) Estimate of regenerative drug and device (surgical) opportunity in peripheral vascular disease. AMI, acute
myocardial infarction.
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on valve engineering has not proceeded to clinical im-
plementation.
To summarize, cardiovascular disease represents the most
significant area of opportunity for regenerative therapies.
Heart failure is the most prominent opportunity within the
cardiovascular space. The development of small-caliber
vascular grafts, while justified based on incidence alone, may
have greater applicability in indications other than coronary
bypass grafting and replacement of heart valves will be
particularly challenging clinically and commercially.
Musculoskeletal diseases
The musculoskeletal category encompasses bone and
cartilage repair as well as tendon and ligament repair, and
connective tissue disease. Many of the opportunities within
this group could be addressed both by cell-based therapy
and acellular biomaterials as well as combination products
developed with tissue engineering.
Arthritis was the most prominent area of opportunity
within the broad category, followed by the incidence of
vertebral disc disorders and osteoporosis. A composite of the
subgroups and EOA data for arthritis and joint applications
is shown in Figure 4. The arthritis target opportunity was
overwhelmingly made up by osteoarthritis. All listed inci-
dence of osteoarthritis averaged 1.8 million discharges per
year supporting published reports on prevalence that project
an unmet and growing medical need.25 Osteoarthritis also
overshadowed the incidence of nonarthritic joint disorders.
This suggests that repair of articular cartilage is the most
prominent orthopedic opportunity over tendon and ligament
repair and well above meniscal disorders and repair.
Examining other orthopedic and skeletal procedures, EOA
data clearly identified the repair of the vertebral discs as the
most prominent skeletal procedure (Fig. 2A) mirroring the
medical need. In contrast, nonunions and malunions, a likely
second target population for a regenerative bone product
ranged from 10,000 to 40,000 per year (Fig. 2A). Two FDA-
approved regenerative bone products containing bone
morphogenetic proteins (BMP-2 bone graft [InFUSE; Med-
tronic]; a BMP-7 collagen putty [OP-1; Stryker]) are used as
part of several repair procedures, most notably spinal fusion
(a treatment for disc disorders). These therapies aid in
achieving fusion of the vertebrae to reduce pain but do not
repair or replace the vertebral disc. The Charite´ artificial disc
(DePuy Spine) is a medical device to replace the disc and
others are in development. Although not perfect solutions,
both types of treatment would be medical competitors to a
regenerative disc therapy. A more substantive examination
of the medical need and opportunity in arthritis and spine
applications will be detailed in Part III of this series, which
reviews the detailed EOA in orthopedics and spine with a
gap analysis of the medical needs as well as the state of the
science and current barriers to translation.
In summary, two cartilaginous tissues make up the major
opportunity in orthopedics and skeletal procedures: the re-
generation of articular cartilage and the repair and regener-
ation of the intervertebral disc. Limiting and/or repairing the
damage caused by osteoarthritis constitutes a major oppor-
tunity for regenerative therapies. The medical needs in major
joint and intervertebral disc disorders are currently ad-
dressed by devices, and in the case of the intervertebral disc,
a device/biologic combination is used. A likely question will
be whether regenerative therapies can delay the use of these
devices or obviate the need for them all together.
Central and peripheral nerve disorders and stroke
Recovery of function following stroke represents the most
prominent treatment opportunity in brain and nerve disor-
ders (Fig. 5A). The incidence of late functional deficits, in-
cluding hemiplegia and hemiparesis (Fig. 5B), is*10% of the
incidence of cerebral infarction. Regenerative therapies are
targeting recovery from motor and mental deficits through
either support or stimulation of regeneration or direct con-
tribution of stem cells that can result in growth and func-
tional differentiation of new neurons and supporting glial
cells.26
There has been biotechnology interest in the use of neural
stem cell therapy to treat motor disorders (Geron Corp.). The
incidence of paraplegia is shown in Figure 5B. Amyotrophic
lateral sclerosis (ALS) accounted for 65%–71% of motor
neuron disorders. When all diagnoses were counted, the
incidence of ALS reached over 8,000 discharges per year.
Degenerative cerebral diseases represent a significant tar-
get population where the medical need is still largely unmet
and the potential to impact quality of life is high (Fig. 5B).
Despite a significant incidence, targeting a degenerative ce-
rebral disease like Alzheimer’s using stem cells is predicted
to be more difficult due to an active degenerative process
and lack of appropriate target cells within the brain.27 In
these indications, stem cells might be used indirectly to de-
liver factors to limit degeneration. This indirect or antago-
nistic mode of action would naturally make it a more
difficult and potentially less-robust medical application and
target opportunity for stem cell therapy.28 Also, methods
needed to deliver the therapy over time may be particularly
difficult compared to a drug approach,27 illuminating the
need to consider how a therapy would be used. The methods
and results should mesh with acceptable medical practice,
risk, and patient needs as well as cost to be an appropriate
match to the target opportunity.
Parkinson’s disease has long been viewed as a prime tar-
get for fetal and stem cell therapy.29 The incidence for Par-
kinson’s disease ranged from 34,000 to 41,000 discharges per
year (Fig. 5C). In Parkinson’s disease the stem cell therapy is
direct. Stable differentiation, integration into the substantia
nigra, and persistence of dopaminergic neurons capable of
producing sufficient amounts of dopamine with lasting effect
will be key to its feasibility and therapeutic value. Of concern
in clinical experience to date is the development of dyskin-
esis30,31 suggesting that knowledge of how to achieve better
integration of the cells may be as important to successful
translation as delivery and differentiation of the cells. There is
a similar hurdle in the use of cardiomyocytes for cardiac repair
where the development of arrhythmia will be the concern.32
In diseases with an etiology of autoimmune or inflam-
matory dysregulation like multiple sclerosis, there is the
possibility of using stem cells as drugs to manage the in-
flammatory response to limit symptoms and possibly pro-
gression.33 This will be true for degenerative spinal cord
disease as well. But by our more stringent definition, a re-
generative therapy for these indications would target stable
remyelination, a more complex and difficult objective but
also one that is (1) of potentially higher value, (2) less likely
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to directly compete with more traditional drug approaches,
and (3) possibly synergistic with immune therapies. While
not all targets in this category will be equally accessible and
the scientific match between technology and target equally
robust, all represent a significant medical need where a
therapy that could improve function and quality of life
would be of high value. A more detailed analysis of the
medical need, mechanism of action, and regulatory paths as
stand-alone or combination therapies will be covered in a
future publication.
In summary, the possibility of intervening to limit neural
degeneration caused by stroke and ultimately recover lost
function through regeneration is attractive and the market
sizable. Restoration of spinal cord function will be critical as
well. The major issues to overcome in these areas are ones of
functional integration within an injured or diseased envi-
ronment, and from a practical perspective, mode of cell de-
livery.
Genetic and metabolic disorders
Restoration of liver cell function constitutes the most
prominent target opportunity within the genetic metabolic
disorders (Fig. 6A). The most prominent liver target is in
disorders of lipid metabolism34 although it is reasonable to
expect that a single technology able to restore liver cell
function could be leveraged to address multiple metabolic
targets (Fig. 6B).35 Leveraging of technology would also be
likely in bone marrow targets. This is in contrast to the
pancreatic islet target for the treatment of diabetes, which is
significantly lower than the single lipid metabolism target for
a liver technology. Both the liver and pancreas are devel-
opmentally related so it is not unreasonable to anticipate that
there will be a comparable level of scientific difficulty in
generating and validating either liver or islet progenitors36
from either embryonic stem cells or induced pluripotent stem
cells. Both have demonstrated some preclinical and early
clinical proof of principle.37–39 The differences between liver
and islet therapies in development, regulatory, and medical
hurdles and how they impact commercial translation will be
reviewed in a future report.
The advances for liver and pancreas transplantation have
followed parallel paths. However both represent very
different kinds of opportunities. A therapy capable of re-
establishing functional liver cells within a disease-compro-






























































osteoarthritis 760,592 826,126 804,998
disc disorders 623,004 560,087 605,237















FIG. 4. A composite of the treatment opportunities for regenerative therapies to treat musculoskeletal disorders in U.S.
hospitalized patients for years 2004–2006. (A) Comparative incidence across major orthopedic areas. (B) The incidence of
osteoarthritis in all discharged patients, and those listing osteoarthritis as the first or second disorder upon discharge. (C)
Estimates of tendon, ligament, and joint disorders. (D) Estimate of meniscal disorders and procedures. Note that the data do
not include procedures done on an outpatient basis.
146 PARENTEAU ET AL.
orphan drug markets. Bone marrow stem cells may also
address multiple disorders. In contrast, approaches to restore
or regenerate pancreatic islets, or more specifically beta cells,
will be most applicable to the smaller type 1 diabetic popu-
lation and then possibly to a niche population within the
large type II diabetic population.
Meeting the medical needs identified in the EOA
Even a top-level analysis of the EOA data made it clear
that many of the most prominent opportunities for regen-
erative therapies would not be realized without significant
scientific progress and innovation. Without major industry
investment and activity, the impetus toward translation
must occur in academia and small companies, primarily
funded through government grants. Our next goal was to
establish objectively a baseline of current research produc-
tivity and innovation in U.S.-funded RMSCR and examine
how well current activities fit with what was learned from
the EOA data.
The NIH recently created a Research, Condition, and
Disease Categorization system in response to the NIH Re-
form Act of 2006. This allowed the collection of data on basic
research funding for regenerative medicine and stem cell
research categories as well as a break-out of ‘‘stem cells’’ and



















Parkinson's 41,185 33,937 39,790
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Disorders 16,892 20,356 28,181
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Paralytic Dis. 83,518 80,631 75,215
Cerebral Pa lsy 17,396 16,212 19,030
Epilepsy 70,182 77,863 94,394
MS 75,461 71,726 75,565




FIG. 5. A composite of the estimate of opportunity for regenerative therapies to treat central and peripheral nerve disorders
in U.S. hospitalized patients for years 2004–2006, including stroke. (A) Comparative incidence across major neurological
areas. (B) Breakdown of neuropathies. (C) Breakdown of degenerative disorders.
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RePORT and an additional RePORT data summary on NIH
Estimate of Funding.17 Research output and early transla-
tional activity were evaluated by measuring the level of
output and innovation attributed to grants awarded by the
NIH funded in fiscal years 2008 and 2009. Projects attributed
to the categories of regenerative medicine and stem cell re-
search were combined to form the RMSCR data set. Ad-
ditionally, projects in all categories were searched by key
terms to form alternative data groups in stem cells and tissue
engineering (not listed by category). Since each project can be
assigned multiple categories and key terms, the data sets
overlapped but were not equivalent. We examined three
contributing factors: (1) U.S. investment in basic and applied
research, (2) U.S. scholarly output measured by linked pa-
pers, and (3) innovation measured by foundational linked
patents and pending patent applications (U.S. Patent data).
Naturally, this analysis is dependent on the accuracy of
NIH’s categorization of funding areas.
U.S. investment in basic and applied research relevant
to regenerative therapies
In general, it appeared that both cardiovascular and neu-
rodegenerative research were supported at levels that re-
flected the medical need (Table 1). The striking exception
was arthritis, which despite its prominence as a regenerative
medicine target, stood out as being significantly under-
supported both as a whole (Table 1) and within the RMSCR
group filtered by key terms (Table 2). Yet RMSCR projects
filtered using ‘‘bone’’ as a key term identified the highest
number of RMSCR projects, even outpacing cancer by a
small margin (Table 2). This suggests that while bone-related
research is appropriately supported, it includes little focus on
arthritis and cartilage regeneration research, indicating a
possible disconnect between research focus and the medical
need as measured by our EOA.
It was clear that stem cell research dominated RMSCR
funding (Table 1). Of the 7,754 projects within the RMSCR
group, only 1,417 projects (18%) categorized as regenerative
medicine did not also fall under stem cell research, approx-
imating the number of projects (1,207) identified by the term
‘‘tissue engineering.’’ Our EOA analysis clearly indicated that
for a clinically effective outcome, many programs would
ideally need to combine stem cell research and tissue engi-
neering expertise (among other areas). Although strong
support of stem cell research alone will provide an important
foundation of basic knowledge, and appears to be doing so
(Table 1), it will be important to see the tissue engineering
grants and the stem cell research grants begin to merge.
The interest in doing stem cell research was understand-
able; however, we wanted to understand more about its
connection to regenerative medicine and also better under-
stand possible reasons for the lack of tissue engineering
support. Table 3 shows the levels of cross-categorization for
grants identified by key terms. Although a higher percentage
of tissue engineering grants were categorized as regenerative
medicine compared with stem cell grants (56% vs. 40%), the







Islet - diabetes 169,355 170,548 180,683
Liver - amino acid 5,808 6,094 8,217
Liver - carbohydrate 5,551 3,808 6,853


































FIG. 6. A composite of the estimate of opportunity for regenerative therapies to treat genetic and metabolic disorders in U.S.
hospitalized patients for years 2004–2006. (A) A detailed incidence of liver-, pancreas-, and bone marrow–associated dis-
orders. (B) The total relative treatment opportunity in liver, pancreas, and bone marrow disorders.
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grants categorized as stem cell research represented 25% of
an already small number of grants compared with 56% for
the much larger stem cell group. Both groups had a nearly
equal number of grants categorized under arthritis, sug-
gesting possible integrated effort although the numbers were
very small (Table 3).
Scholarly output and innovation
Publications, patent base, and pending patents were
studied to gain a sense of output that could impact transla-
tion. Output data reported by the NIH RePORTer system
were used to compare RMSCR to other categories of research
(Table 1). Publications were those identified as linked to the
current research in some way. Since patents take several
years to issue once filed, the linked patents in the RePORTer
database appeared to past as well as present intellectual
property and thus represented a base of technology rather
than direct output of the current research. In addition to
category and group data, data on institutions with 10 or
more unique RMSCR projects in 2008–2009 and ‡ $10M in
funding were collected to more closely examine the distri-
bution of knowledge generation and innovation, this time
adding pending patent information gathered from the Uni-
ted States Patent and Trademark Office (USPTO). One can
debate the relative importance of each component, but the
translational success of a research program will be related to a
combination of its scientific and technical foundation, as well
as the current degree of innovation and level of scholarly
output. Therefore, a picture of them together gives us some
idea of relative performance and potential in the near term.
The relative performance of the Tissue Engineering group in
this analysis is not straightforward to understand (Table 1).
Gene Therapy and Arthritis, despite a similar level of support,
reported significantly higher numbers of linked publications
and patents. Bioengineeringwaswell funded. It is possible that
researchers are no longer using the term ‘‘tissue engineering’’ to
describe their work, but a term search of bioengineering
Table 1. Relative Ranking of Regenerative Medicine, Stem Cell Research and Tissue Engineering
Amongst Major Research Categories
Ranked by













1 Cancer 111,990 32,840 58,208 1,541 2.2 2.3
2 Bioengineering 60,080 18,843 45,410 964 10.6 10.4
3 Aging 49,800 17,424 38,019 659 2.4 2.1
4 Cardiovascular 40,350 11,856 27,317 477 2.5 2.1
5 Neurodegenerative 31,740 11,030 23,913 514 29.9 2.5
6 Stem cell (by term) 30,440 8,379 20,065 647 1.6 1.8
7 Diabetes 21,100 5,737 14,349 249 2.3 2.2
8 SCR 19,820 8,379 20,065 647 1.6 1.3
9 RM 15,220 7,754 19,230 549 2.4 1.5
10 Obesity 14,090 4,685 12,118 141 1.1 1.0
11 Nanotechnology 6,470 2,191 6,358 148 2.7 3.0
12 Arthritis 4,780 1,688 6,223 99 3.6 3.1
13 Gene therapy 4,700 1,542 6,103 281 2.7 3.0
14 Tissue engineering (by term) 3,758 1,207 2,507 29 5.0 4.6
SBIR/STTR, small business innovational research and technology transfer grants; SCR, stem cell research; RM, regenerative medicine.
Bold text highlights RMSCR research by category or term.
Table 2. Regenerative Medicine and Stem

















RMSCR, Combined regenerative medicine and stem cell research
categories.
Table 3. Comparative NIH Spending on Stem














Both RM and SCR 1,136 91
RM but not SCR 92 119






aProjects can be attributed to more than one category.
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projects using the terms ‘‘regenerative medicine’’ or ‘‘tissue
engineering’’ each identified < 1,000 projects among the 18,843
projects in the category. Another possibility is that the interest
in stem cells has attracted the government and this has influ-
enced investigator interest, resulting in fewer tissue engineer-
ing grants being submitted. A third possibility is that while
stem cell research is still clearly in a research phase, tissue
engineering has been around longer and has had a heavily
applied focus. Therefore, tissue engineering projects are less
likely to be viewed as new, innovative research. There ap-
peared to be insufficient support for tissue engineering relative
to the EOA, but the projects that were funded had a compar-
atively low level of productivity. This suggests that it is more
difficult to produce publishable results in tissue engineering or
conversely, it is easier to get stem cell work published. This
could be due to the nature and novelty of stem cell work over
tissue engineering, the increasingnumber of journals to publish
stem cell work, and general interest in stem cell biology.
Indeed, the overall strong showing for RMSCR appeared pri-
marily due to stem cell research. However these data represent
a total of all activities and a natural question emerges: are there
readily identifiable clusters of excellence, or does the total
reflect the overall state of a field like tissue engineering and
how is the know-how in stem cell research distributed?
Analysis of the 58 most active RMSCR institutions (ex-
cluding institutions with a principal focus on cancer) re-
vealed several surprises. As we might expect, there was
some correlation between funding and linked publications
(correlation = 0.42) and the linked base of patents (correla-
tion = 0.68); however, when we broke out groups by major
U.S. biotechnology regions for a detailed look, an interest-
ing picture emerged (Table 4). The Boston area (Eastern
MA) is home to nine of the top RMSCR institutions and
represented a range of funding levels. While attribution of
publications and patents is somewhat dependent on in-
vestigator reporting and can be subjective, the trend that
emerged was one of output variability, particularly in the
patent area. This variability was supported by the objective
number of pending patent applications. Of note were two
institutions that had a strong patent base and future patent
potential. Also, a lesser-funded institution with a modest
patent base exhibited a strong showing in RMSCR patent
applications. Investigators within the institutions appear to
value intellectual property differently and do not appear to
be positively influenced by proximity to highly innovative
institutions or an entrepreneurial environment. The top 1
and 3 ranked institutions were from northern California.
Given their level of funding, these institutions had both a
limited self-reported intellectual property base and future
patent potential. The level of patent activity was not mir-
rored by linked publications. The data suggest that inves-
tigators in these institutions either do not self-report patent
activity or are focused on research less likely to lead to
patentable innovations. Southern California had a distri-
bution of funding similar to the Boston area with two in-
stitutions appearing to be making strides in the generation
of new RMSCR intellectual property. Undoubtedly, with 58
institutions conducting 10 or more projects and funded at
Table 4. Regional Differences in Funding and Productivity in Major Biotechnology Hubs
Funding rank among most








7 $48,158,409 283 12 3
8 $41,097,558 180 4 4
14 $33,778,188 134 1 0
26 $21,944,041 286 37 23
33 $19,318,532 183 19 9
41 $14,696,506 147 0 2
47 $13,458,151 102 0 1
50 $12,382,457 86 0 5
54 $11,202,036 62 3 10
Total funding $216,035,878
Region: Northern CA
1 $69,230,915 404 8 8
3 $60,042,302 316 10 b
Total funding $129,273,217
Region: Southern CA
11 $36,413,010 528 7 b
18 $29,295,268 452 7 b
24 $23,269,184 73 1 7
29 $21,080,319 59 1 13
37 $16,762,233 108 5 b
43 $14,256,843 132 8 1
55 $11,049,652 186 10 b
Total funding $152,126,509
bUniversity of CA $164,555,957 63
aRepresents RMSCR patent applications in the USPTO with the institution as assignee. The current rate of allowance for applications in the
United States is 0.47.42
USPTO, United States Patent and Trademark Office.
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‡ $10M, investment in the field is spread across many in-
stitutions averaging out differences, at least for stem cell
research. We also compared funding for projects identified
by the terms ‘‘tissue engineering’’ and ‘‘stem cells’’ for the
top RMSCR institutions (Fig. 7). It is clear that very few
institutions have a major tissue engineering effort and no
RMSCR institution received more funding to conduct tissue
engineering research than stem cell–related research.
Small business innovation and technology transfer
Small business support through the small business inno-
vational research and technology transfer grants (SBIR/
STTR) is an important stepping stone for university tech-
nologies. We broke out SBIR/STTR projects to measure the
support of small business activity within the major research
areas (Table 1). Small business projects and funding of
RMSCR were in-line with other categories and accounted for
a fairly consistent 1%–3% of the total projects and funding
within a research category, regardless of the category’s
overall level of output and innovation.
Discussion
The estimate of opportunity analysis
While medical device companies are steadily adding bi-
ological sophistication to their products and some large
pharmaceutical companies are establishing internal exper-
tise in stem cell biology, internal and external investment
must be justified with a clear view of how those invest-
ments can lead to products that will impact patient care. In
addition, the ability to leverage an investment in specialized
expertise and processes for a niche market will be key to
justify the investment needed to advance many regenera-
tive technologies. This requires a clear picture of the treat-
ment opportunities. Basic research and commercial efforts
alike are in need of target-based data that can be matched to
and analyzed against a particular technology and medical
strategy for reaching it. As we have shown, EOA data can
help identify:
 Synergies and opportunities for leveraging technology
and know-how
 Likely reimbursement (and regulatory) issues
 The medical value needed for successful adoption and
commercialization
 Knowledge and technology gaps
Use of target-based EOA data for pipeline analysis may
reduce development risk by directing efforts to the most
feasible, high-impact applications—even from the earliest
stage of innovation. EOA data can also provide clarity with
respect to the best path for a technology.
Asmentioned in this report, we are preparingmore detailed
analyses in the key medical areas identified in this report.
 Cardiovascular and peripheral vascular disorders
 Orthopedic and spine disorders
 Central and peripheral nervous system disorders
including stroke
These reviews will include EOA detail down to individual
disorders, gap analyses of the major medical needs identified
by the EOA, and in some cases, additional analysis of sci-
entific barriers to progress.
Despite abundant target opportunities, innovative regen-
erative medicine, like all therapies, must meet the medical
need with therapies capable of delivering value to the patient
and the medical system. Without it, reimbursement will
continue to be challenged, and business models will remain
unconvincing to potential investors. Apart from an initial
burst of commercial activity 20 years ago that led to U.S.
approvals for regenerative biomaterials (Integra Dermal Re-
generation Scaffold; Integra Life Sciences), the first device
and biologic cell therapies (Regranex, Johnson and Johnson;
InFuse, Medtronic) and tissue engineered combination
products (Apligraf, Organogenesis Inc.; Dermagraft, Ad-
vanced Tissue Sciences and Smith and Nephew [acquired by
Advanced BioHealing]), academia, and industry alike have
struggled to expand the list.40
The osteoarthritis target opportunity is one of the most
significant treatment opportunities for a regenerative
therapy. Effective cartilage repair would reduce the need
for knee replacement surgery, and a cartilage repair pro-
cedure would likely increase the quality of life for many
more patients at a cost savings to the medical system if
less than the current cost for knee replacement. The inci-
dence of knee replacement surgeries in the U.S. popula-
tion doubled for patients aged 45–64 between 2000 and
FIG. 7. Proportion of tissue engineering funding in the top NIH-funded institutions in regenerative medicine and stem cell
research. Data source: NIH RePORTer database.16 Projects were identified by the terms ‘‘tissue engineering’’ or ‘‘stem cells.’’
NIH, National Institutes of Health.
MEETING THE NEED FOR REGENERATIVE THERAPIES 151
2006 and in those 65 and older rose from 60.1 to 88.0 per
10,000.15 However, there are regenerative products and
procedures currently available that have gained only
modest acceptance. How much better does a second-
generation cartilage therapy have to be to justify invest-
ment in the development of a next generation product?
Evaluate Pharma Ltd. reported worldwide sales of Carti-
cel (Genzyme Biosurgery) of $25M for 2008, an increase
of 4% over 2007—after 11 years (Evaluate Pharma Ltd.).
This indicates that regenerative therapies for cartilage
repair must become significantly better. Venture capital
remains unconvinced that a critical mass of science and
technology has yet been combined to achieve this ( Jeffrey
Koran, personal communication) although there is some
evidence of a move in that direction with the recent
merger of two cartilage repair companies: Histogenics and
Prochon. Both large and small companies have struggled
with advancing a regenerative cartilage therapy suggest-
ing that financing is not the principal roadblock. It is ev-
ident that additional knowledge and innovation is needed
and that targeted investment from NIH could have a
significant impact. Further investigations focused on bet-
ter enabling the use of mesenchymal or other stem or
progenitor cells in cartilage regeneration would be an ef-
fective starting point.41
While we have highlighted the most prominent opportu-
nities in the major disease categories, a small target population
is not in itself a limiting factor as is evident from the growing
interest in orphan indications and personalized medicine.
For example, the low incidence of muscular dystrophy may
qualify it for orphan drug and device status, which is based on
a U.S. prevalence of < 200,000.42 However, an important
consideration for the commercialization of orphan regenera-
tive therapies compared to the highly lucrative biologics like
antibodies (e.g., Alexion’s Soliris) or enzymes (e.g., Gen-
zyme’s Cerezyme) will be that regenerative therapies be-
yond molecules will involve more limited or finite dosing and
ideally will lead to long lasting results. Depending on the type
of therapy, method of delivery, and target, persistent results
lasting years may in fact be a prerequisite to approval and
acceptance by regulators, patients, and clinicians. A $250,000
yearly cost per patient for an orphan biologic may translate to
$250,000 per patient over several years, or the life of the pa-
tient, for a regenerative therapy. This model would drive a
very high cost per treatment for orphan regenerative (cura-
tive) treatments that may not be tolerated by payers without
evidence of cost savings over time.
The EOA suggests that not every technology and indi-
cation pairing will be equally feasible or valuable—
for varying reasons. While top-level analysis of the EOA
data provides important perspective and directs us to the
major regenerative targets, assessment of a technology’s po-
tential to address a specific medical need will require drilling
down to the details of the science, technology, medical need,
and target patient populations using the EOA data as a road
map. Our theory is that an ever clearer understanding of the
target opportunities should help academics more readily
identify key knowledge gaps and more clearly recognize the
opportunities for discovery and innovation in their research—
improving the efficiency and effectiveness of translation. We
will shortly publish a series of such analyses in each of the
main clinical areas.
Analysis of U.S. research output and innovation
in RMSCR
The category and institutional analyses leave little doubt
that further focusing of investment toward areas of greatest
scientific and medical need could improve the current re-
turn on investment in tissue engineering. This, and other
conclusions of our study, echoes recent conclusions on
bioscience progress from the BIGT, which advised that
‘‘universities must think and act more strategically’’ and
build a critical mass of knowledge in a particular subject
or sector.6
U.S. policy on embryonic stem cell research is often cited
as a limiting factor in the pace of discovery in regenerative
therapies. Interestingly, most of the opportunities identified
in our analysis do not hinge on the use of embryonic stem
cells.
Government funding alone, in most cases, will be insuf-
ficient to advance a technology through to FDA approval
and commercialization. Government funding is not a sub-
stitute for private sector investment, though it can be a
positive catalyst for this investment. This will require a
critical mass of knowledge and innovation to support the
connectivity between a technology and treatment target. Of
particular interest will be the factors that generate actionable
knowledge and patents that enable RMSCR products. Im-
proved patent output should enhance the return on research
investment. The need for greater innovation is not specific to
RMSCR as U.S. academic patents in biotechnology have
declined nearly 50% from highs reached between 1998 and
2001.43 Also, the lack of crossover between the tissue engi-
neering and stem cell research spheres could be a factor in
the pace at which RMSCR to advances in key areas of
medical need going forward.
The EOA data provide substantial evidence of the clinical
and commercial potential of regenerative medicine—as stem
cell therapies and tissue engineering, as orphan biologics,
and as therapies to fill large unmet medical needs. As in any
new field, translating regenerative science is not without its
challenges. We have concluded that identifying the chal-
lenges and studying them from a scholarly perspective is a
critical step in understanding how to overcome them. It is
our hope that this and future EOA analyses will help those
involved in the field to target scientific, clinical, and com-
mercial pursuits in a way that can sustainably generate high-
value regenerative therapies that represent a critical part of
the future of medicine.
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